Deborah Collyar: What's In It for Patients?

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Dec

Today In Oncology

Adding Durvalumab to Chemoradiotherapy in Locally Advanced Cervical Cancer

First-Line Treatment of Advanced HCC Addition of Pembrolizumab to Lenvatinib

Everolimus for Pediatric Recurrent/Progressive Low-Grade Glioma

Chronic Health Conditions May Be Prevalent Among LGB Adolescent and Young Adult Cancer Survivors

Lung-MAP Trial Demonstrates Potential of Public-Private Partnerships in Advancement of Cancer Therapy

Deborah Collyar: What's In It for Patients?

Related Videos